FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 27, 2015--
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the promotion of
William Lee, PhD to Executive Vice President, Research, and Brett
Pletcher to Executive Vice President and General Counsel. Dr. Lee and
Mr. Pletcher will both join Gilead’s senior leadership committee.
Dr. Lee joined Gilead in 1991 and was promoted to Senior Vice President,
Research in 2000. He has led the expansion of the company’s research
activities across a range of therapeutic areas, including HIV, liver
diseases, hematology/oncology, inflammation and respiratory diseases and
cardiovascular conditions. He reports to Norbert Bischofberger, PhD,
Executive Vice President, Research and Development and Chief Scientific
Officer. Prior to joining Gilead, Dr. Lee worked at California
Biotechnology, Inc. and Syntex. He received his BS in Chemistry from the
University of Massachusetts, PhD in Chemistry from the University of
California at San Diego and did postdoctoral work at the Ecole Polytech
Federal Lausanne and the University of California at Santa Barbara.
“Over the past nearly 25 years, Bill has helped Gilead bring multiple
product candidates from early stage research into development. His
contributions to the discovery and advancement of internal drug
candidates and evaluation of external candidates for potential
partnership have allowed Gilead to bring important new medicines to
patients around the world,” commented Dr. Bischofberger.
Mr. Pletcher joined Gilead in 2005 and most recently served as Senior
Vice President and General Counsel. With this promotion, Mr. Pletcher
also becomes corporate Secretary for the company. He reports to Gregg
Alton, Executive Vice President, Corporate and Medical Affairs. Prior to
joining Gilead, Mr. Pletcher was a partner in the law firm of Gunderson
Dettmer, LLP, where he focused on providing corporate and securities
services to emerging growth public and private companies and venture
capital investors. He received his bachelor’s degree in economics and
political science from the University of California, Riverside and his
law degree from the University of California, Berkeley’s Boalt Hall
School of Law. He is a member of the California State Bar and the Nasdaq
Listing and Hearing Review Council.
“Brett’s leadership has been instrumental in helping Gilead manage a
period of significant growth and complexity, particularly as we
introduce medicines in new geographies. His expertise has helped Gilead
protect its intellectual property around the world and ensure compliance
across countries with vastly different legal systems,” commented Mr.
Alton.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 30
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.Gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150727006228/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.Investors:Patrick O’Brien, 650-522-1936MediaAmy
Flood, 650-522-5643
